Targeting Multiple Hallmarks of Skin Aging: Preclinical and Clinical Efficacy of a Novel Growth Factor-Based Skin Care Serum

• TR Number: 1011
• Keywords: EpiDerm-FT (EFT-400), Anti-aging, Skin rejuvenation, skin care serum, proteasome, autophagy, stemness, connexins, UVB treatment, solar simulator, intercellular communication, extracellular matrix (ECM), epidermal barrier, COL1A1, COL3A1, COL4A1, COL7A1, ELN, FBN1, TGFB1, POMP, PSMB5, PSMB6, ATG5, ATG7, ATG12, BECN1, MAP 1LC3A, ACTA2, NES, CX37 GJA4, CX26 GJB2, CX30.3 GJB4, CX31.1 GJB5, CX30 GJB6, IVL, UGCG, OCLN, TGM1, TGM3, SPRR1A, SMPD1, cell senescence, cosmeceuticals

The aging process involves numerous biological mechanisms that have been characterized and proposed as the ‘‘hallmarks of aging.’’ Targeting the processes and pathways related to these hallmarks of aging that cause and promote skin aging could provide anti-aging benefits. A novel topical growth factor-based skin care serum (A+) was developed using human fibroblast conditioned media. This study aimed to assess the effects of A+ on four hallmarks of aging and its clinical efficacy in skin rejuvenation in subjects with moderate to severe overall facial photodamage.